Indiana University School of Medicine – Developmental Therapeutics Review – Q4 2010

Date: December 1, 2010
Pages: 66
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: IE064AA1EC0EN
Leaflet:

Download PDF Leaflet

Indiana University School of Medicine – Developmental Therapeutics Review – Q4 2010
Indiana University School of Medicine – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Indiana University School of Medicine – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope
  • Review of therapeutics under development by Indiana University School of Medicine.
  • Overview of products under development across various therapy areas.
  • Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Indiana University School of Medicine with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of Indiana University School of Medicine’s therapeutic products in the last quarter.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify new drug targets and therapeutic classes in Indiana University School of Medicine’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
  • Evaluate Indiana University School of Medicine’s position with total access to a detailed information on its therapeutic products development.
  • Assess the growth potential of Indiana University School of Medicine in its therapy areas of focus.
  • Exploit collaboration and partnership opportunities with Indiana University School of Medicine.
  • Avoid Intellectual Property Rights related issues.
Indiana University School of Medicine Snapshot
Indiana University School of Medicine Overview
Key Information
Key Facts
Indiana University School of Medicine – Research and Development Overview
Key Therapeutic Areas
Indiana University School of Medicine – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Indiana University School of Medicine – Pipeline Products Glance
Indiana University School of Medicine – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Indiana University School of Medicine Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Indiana University School of Medicine–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Indiana University School of Medicine – Drug Profiles
Atomoxetine + Clozapine
  Product Description
  Mechanism of Action
  R&D Progress
Basiliximab + Cyclosporine
  Product Description
  Mechanism of Action
  R&D Progress
Doxorubicin + Docetaxel
  Product Description
  Mechanism of Action
  R&D Progress
Doxorubicin + Paclitaxel
  Product Description
  Mechanism of Action
  R&D Progress
Alimta_
  Product Description
  Mechanism of Action
  R&D Progress
Aripiprazole
  Product Description
  Mechanism of Action
  R&D Progress
Basiliximab
  Product Description
  Mechanism of Action
  R&D Progress
Carboplatin + Decitabine
  Product Description
  Mechanism of Action
  R&D Progress
celecoxib
  Product Description
  Mechanism of Action
  R&D Progress
Decitabine + Carboplatin
  Product Description
  Mechanism of Action
  R&D Progress
Erlotinib + Bevacizumab
  Product Description
  Mechanism of Action
  R&D Progress
N-Acetylcysteine
  Product Description
  Mechanism of Action
  R&D Progress
Pazopanib
  Product Description
  Mechanism of Action
  R&D Progress
Perillyl Alcohol
  Product Description
  Mechanism of Action
  R&D Progress
Revlimid + Cyclophosphamide + Prednisone
  Product Description
  Mechanism of Action
  R&D Progress
Sitagliptin
  Product Description
  Mechanism of Action
  R&D Progress
sunitinib + paclitaxel + doxorubicin + cyclophosphamide
  Product Description
  Mechanism of Action
  R&D Progress
Venlafaxine
  Product Description
  Mechanism of Action
  R&D Progress
ZD1839
  Product Description
  Mechanism of Action
  R&D Progress
cilengitide
  Product Description
  Mechanism of Action
  R&D Progress
Clofarabine + HD Etoposide + Cyclophosphamide + APBSCT
  Product Description
  Mechanism of Action
  R&D Progress
EMD 121974
  Product Description
  Mechanism of Action
  R&D Progress
Fondaparinux
  Product Description
  Mechanism of Action
  R&D Progress
Gemcitabine + Sorafenib + Radiation Therapy
  Product Description
  Mechanism of Action
  R&D Progress
Gleevec_
  Product Description
  Mechanism of Action
  R&D Progress
PTK787 + Paclitaxel
  Product Description
  Mechanism of Action
  R&D Progress
RAD001 + AMG479
  Product Description
  Mechanism of Action
  R&D Progress
Recombinant interleukin-12
  Product Description
  Mechanism of Action
  R&D Progress
Sorafenib + Vorinostat
  Product Description
  Mechanism of Action
  R&D Progress
Tacrolimus + Sirolimus + Bortezomib
  Product Description
  Mechanism of Action
  R&D Progress
Tarceva + Gemcitabine + Radiotherapy
  Product Description
  Mechanism of Action
  R&D Progress
Aripiprazole
  Product Description
  Mechanism of Action
  R&D Progress
Indiana University School of Medicine – Pipeline Analysis
Indiana University School of Medicine – Pipeline Products by Therapeutic Class
Indiana University School of Medicine Pipeline Products By Target
Indiana University School of Medicine – Pipeline Products by Route of Administration
Indiana University School of Medicine – Pipeline Products by Molecule Type
Indiana University School of Medicine - Dormant Projects
Indiana University School of Medicine – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Indiana University School of Medicine – Pipeline by Therapy Area and Indication, 2010
Indiana University School of Medicine – Pipeline by Stage of Development, 2010
Indiana University School of Medicine – Monotherapy Products in Pipeline, 2010
Indiana University School of Medicine – Combination Treatment Modalities in Pipeline, 2010
Indiana University School of Medicine – Phase III, 2010
Indiana University School of Medicine - Phase II, 2010
Indiana University School of Medicine - Phase I, 2010
Indiana University School of Medicine - Pipeline By Therapeutic Class, 2010
Indiana University School of Medicine - Pipeline By Target, 2010
Indiana University School of Medicine – Pipeline By Route of Administration, 2010
Indiana University School of Medicine – Pipeline By Molecule Type, 2010
Indiana University School of Medicine - Dormant Developmental Projects, 2010
Indiana University School of Medicine, Other Locations 63

LIST OF FIGURES

Indiana University School of Medicine – Pipeline by Therapy Area and Indication, 2010
Indiana University School of Medicine – Pipeline by Stage of Development, 2010
Indiana University School of Medicine – Monotherapy Products in Pipeline, 2010
Indiana University School of Medicine – Combination Treatment Modalities in Pipeline, 2010
Indiana University School of Medicine – Pipeline By Therapeutic Class, 2010
Indiana University School of Medicine - Pipeline By Target, 2010
Indiana University School of Medicine – Pipeline By Route of Administration, 2010
Indiana University School of Medicine – Pipeline By Molecule Type, 2010 61

Ask Your Question

Indiana University School of Medicine – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: